ArticleBiology methods & protocols2025
Cell2Read: an automated workflow to generate sequencing-ready DNA libraries from human cell suspensions.
Article in Biology methods & protocols, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cell2Read is a novel automated method for complete integration of cell lysis and sample preparation for next-generation sequencing (NGS). It optimizes diffusion kinetics and complex thermal geometries to allow for effective use down to low inputs of cells. This allows for DNA analysis from a low cellular input, whether this be for in vitro analysis or diagnostic applications from dissociated tumor biopsies. We demonstrate that the system can process input cell suspensions as low as 1500 cells without compromising sequencing integrity. We also demonstrate the breadth of the protocol in its ability to repeatably process many cell types, including HepG2, Caov3, HEY A8, OVCAR 8, MDA-MB-231, and Human Primary Ovarian Epithelial Cells. The workflow integrates and fully automates cell lysis, DNA extraction, and library preparation into a single automated platform, offering high sensitivity and reproducibility. Our results show that the system yields consistent DNA quantities (≥10 ng) with high sequencing quality, even at low cell inputs, with alignment rates exceeding 95% for inputs of 3125 cells or greater. The automated method's sequencing performance was comparable to manual protocols, with no significant differences in quality scores or GC bias across processing methods. We also demonstrated effective, non-biased sequencing of heterogeneous cell suspensions, through comprehensive testing of spiked concentrations of cancerous cells with non-cancerous ovarian cells. Sequencing output showed proportional DNA representation of cancer markers to the concentration of cancer cells inputted. The Cell2Read workflow offers a technically validated, scalable solution that expands accessibility to genomic analysis and supports reproducible, high-quality sequencing from low-input human samples. This robustness across a range of cell types, makes Cell2Read an ideal solution for sequencing applications, including oncology research and clinical diagnostics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.